Dr. Hirawat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Cross Gates Rd
Madison, NJ 07940Phone+1 201-787-5392
Education & Training
- Zucker School of Medicine at Hofstra/NorthwellFellowship, Hematology and Medical Oncology, 1999 - 2002
- Zucker School of Medicine at Hofstra/Northwell at Forest Hills HospitalResidency, Internal Medicine, 1996 - 1999
- Sawai Man Singh Medical CollegeClass of 1994
Certifications & Licensure
- NJ State Medical License 2004 - 2025
Publications & Presentations
PubMed
- 84 citationsTargeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.Neil A. O'Brien, M McDermott, Dylan Conklin, Tong Luo, Raul Ayala
Breast Cancer Research. 2020-08-14 - 1343 citationsAlpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast CancerFabrice Andre, Eva Ciruelos, G. Rubovszky, Mario Campone, Sibylle Loibl
The New England Journal of Medicine. 2019-05-15 - 573 citationsRibociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia
The Lancet. Oncology. 2018-07-01
Press Mentions
- Cobenfy Approved as First-in-Class Treatment for SchizophreniaOctober 1st, 2024
- FDA Approves First New Drug for Schizophrenia in More Than 30 YearsSeptember 27th, 2024
- FDA Approves Bristol Myers Squibb's Schizophrenia Drug, the First New Type of Treatment in DecadesSeptember 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: